Table 3.

Stratification Analysis of Associations between rs11614913 Genotypes and Severe Overall Toxicity by Selected Variables

Selected variables	rs11614913	Group 1a	Group 2b	P	OR (95% CI)c
Chemotherapy regimens
Platinum‐navelbine	CT+TT	87	55		1.00 (reference)
	CC	24	27	0.07	1.81(0.94–3.48)
Platinum‐gemcitabine	CT+TT	35	10		1.00 (reference)
	CC	11	14	0.006d	4.46 (1.55–12.82)
Platinum‐paclitaxel	CT+TT	43	13		1.00 (reference)
	CC	21	4	0.54	0.68 (0.20–2.36)
Platinum‐based drug
Cisplatin	CT+TT	113	68		1.00 (reference)
	CC	40	48	0.008d	2.04 (1.20–3.48)
Carboplatin	CT+TT	61	20		1.00 (reference)
	CC	23	6	0.74	0.84 (0.30–2.37)
Gender
Male	CT+TT	124	60		1.00 (reference)
	CC	47	41	0.02d	1.92 (1.13–3.25)
Female	CT+TT	50	28		1.00 (reference)
	CC	16	13	0.42	1.46 (0.60–3.57)
Age
≤57	CT+TT	90	36		1.00 (reference)
	CC	36	31	0.01d	2.23 (1.91–4.16)
>57	CT+TT	84	52		1.00 (reference)
	CC	27	23	0.36	1.39 (0.71–2.69)
TNM stage
Ⅲ	CT+TT	75	29		1.00 (reference)
	CC	28	19	0.09	1.88 (0.90–3.94)
Ⅳ	CT+TT	100	59		1.00 (reference)
	CC	35	35	0.08	1.68 (0.94–2.98)
Histological types
Adenocarcinoma	CT+TT	104	53		1.00 (reference)
	CC	44	34	0.15	1.54 (0.87–2.70)
Squamous cell	CT+TT	33	18		1.00 (reference)
	CC	10	10	0.23	1.93 (0.66–5.63)

^aGroup 1 means any grade 1 or 2 overall toxicity.

^bGroup 2 means any grade 3 or 4 overall toxicity.

^cData were calculated by unconditional logistic regression, adjusting covariates were performance status and type of treatment regimen.

^dData of statistical significance.

OR, odds ratios; CI, confidence intervals; TNM, tumor/node/metastasis.